Lakewood Capital Management LP Makes New $61.42 Million Investment in IQVIA Holdings Inc. $IQV

Lakewood Capital Management LP purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 317,900 shares of the medical research company’s stock, valued at approximately $61,425,000. IQVIA makes up 3.2% of Lakewood Capital Management LP’s holdings, making the stock its 11th largest position. Lakewood Capital Management LP owned 0.19% of IQVIA as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in IQV. BlackRock Inc. bought a new position in IQVIA during the 2nd quarter worth $2,811,292,000. Boston Partners bought a new position in shares of IQVIA in the third quarter worth $676,698,000. Norges Bank acquired a new position in IQVIA in the fourth quarter valued at about $497,445,000. Victory Capital Management Inc. lifted its position in IQVIA by 2,628.1% during the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock worth $377,670,000 after purchasing an additional 1,614,063 shares during the period. Finally, Legal & General Group Plc bought a new position in IQVIA in the 2nd quarter valued at about $211,342,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Up 0.2%

Shares of NYSE:IQV opened at $260.30 on Tuesday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $261.88. The company has a market capitalization of $42.85 billion, a PE ratio of 32.30, a price-to-earnings-growth ratio of 2.21 and a beta of 1.18. The company has a fifty day moving average of $214.97 and a 200-day moving average of $187.62.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same quarter in the previous year, the company posted $2.81 EPS. IQVIA’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a stock repurchase program on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Insider Transactions at IQVIA

In related news, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the sale, the insider directly owned 1,348 shares in the company, valued at $317,143.96. This trade represents a 57.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares in the company, valued at $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 12,913 shares of company stock valued at $3,098,793. 1.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

IQV has been the topic of several analyst reports. Mizuho increased their price target on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. TD Cowen raised their target price on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Morgan Stanley reissued an “equal weight” rating and set a $200.00 price target (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Finally, JPMorgan Chase & Co. upped their price objective on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $241.88.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.